Laddar...
Expanded use of rituximab in the management of non-Hodgkin lymphoma
Rituximab is a chimeric monoclonal antibody targeting the B cell antigen CD20. Since its first approval for clinical use in 1997, rituximab has become an inherent part of the treatment of CD20-positive lymphoma. In previously untreated non-Hodgkin lymphoma (NHL) conventional chemotherapy supplemente...
Sparad:
| Huvudupphovsmän: | , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove Medical Press
2009
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2886316/ https://ncbi.nlm.nih.gov/pubmed/20616906 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|